Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 401–500 of 1,004
Designing live bacterial therapeutics for cancer
Lee, J., McClure, S., Weichselbaum, R. R., & Mimee, M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115579 · Cited by 35
Microbiota-Derived Inosine Programs Protective CD8 T Cell Responses Against Influenza in Newborns
Stevens, J., Culberson, E., Kinder, J. M., Ramiriqui, A., Gray, J. K., Bonfield, M., Shao, T., Gharaibeh, F. N. A., Peterson, L. S., Steinmeyer, S. H., et al. (2024) · Cell · doi:10.1016/j.cell.2025.05.013 · Cited by 35
Dong, J., Gao, H.-L., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188484 · Cited by 31
The Microbiome and Its Implications in Cancer Immunotherapy
Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31
Liu, X., Tang, H. T., Zhou, Q., Zeng, Y., Lu, B., Chen, D., Li, Y., Qian, J., Chen, M., Zhao, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109281 · Cited by 35
“found that the microbiome could modulate ICI efficacy through the actions of the bacteria-derived metabolite inosine (39), there are still very few studies on the mechanism of action of microbiota and irAEs.”
BackgroundZheng, D., Qiao, J., Ma, J., An, J., Yang, C., Zhang, Y., Cheng, Q., Rao, Z., Zeng, S., Wang, L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202300977 · Cited by 31
Guo, W., Tang, X., Zhang, Q., Zhao, J., Mao, B., Zhang, H., & Cui, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813852 · Cited by 33
“proved that microbiome-derived inosine enhanced the efficacy of checkpoint inhibitor immunotherapy in colorectal cancer by regulating the host’s immune system [14].”
BackgroundLiu, S., Li, D., Liu, J., Wang, H., Horecny, I., Shen, R., Zhang, R., Wu, H., Hu, Q., Zhao, P., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s326178 · Cited by 30
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102125 · Cited by 29
Zuend, C. F., Lamont, A., Noël‐Romas, L., Knodel, S., Birse, K., Kratzer, K., McQueen, P., Perner, M., Ayele, H., Mutch, S. A., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01594-y · Cited by 32
“Increases in microbiome-derived inosine can promote antitumor immunity, which is dependent on the activation of CD4+ Th1 cells [89].”
BackgroundSelective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity
Hu, Y., Sarkar, A., Song, K., Michael, S., Höök, M., Wang, R., Heczey, A., & Song, X. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101530 · Cited by 39
Xu, X., Chen, Z., Bartman, C., Xing, X., Olszewski, K. L., & Rabinowitz, J. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.007 · Cited by 37
Crouch, L. I., Rodrigues, C. S., Bakshani, C. R., Tavares-Gomes, L., Gaifem, J., & Pinho, S. S. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101891 · Cited by 31
Disentangling the molecular mystery of tumour–microbiota interactions: Microbial metabolites
Duan, Y.-W., Dai, J.-H., Lu, Y.-Q., Qiao, H., & Liu, N. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70093 · Cited by 31
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 33
“It should also be mentioned that gut microbiota can shape TME by modulating the immune and hormonal factors throughout the host (97, 98).”
BackgroundBird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 31
You, L., Zhou, J., Xin, Z., Hauck, J. S., Na, F., Tang, J., Zhou, X., Lei, Z., & Ying, B. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac005 · Cited by 35
Hersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Sampsell, K., Wang, W., Ohland, C., Mager, L. F., Pett, N., Lowry, D. E., Sales, K. M., McNeely, M. L., McCoy, K. D., Culos-Reed, S. N., et al. (2022) · Cancers · doi:10.3390/cancers14112722 · Cited by 30
“Harnessing the potential of the gut microbiota to improve treatment efficacy and health outcomes in cancer populations is of great clinical interest [4,8,9].”
BackgroundSelf-citationIntestinal Uptake and Tolerance to Food Antigens
Xiong, Y., Xu, G., Chen, M., & Ma, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906122 · Cited by 34
Png, C. W., Chua, Y. K., Law, J.-H., Zhang, Y., & Tan, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-14203-z · Cited by 32
Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy
Shelkey, E., Oommen, D., Stirling, E. R., Soto‐Pantoja, D. R., Cook, K. L., Lu, Y., Votanopoulos, K. I., & Söker, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13930-7 · Cited by 31
Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Zhou, P., Hu, Y., Wang, X., Shen, L., Liao, X., Zhu, Y., Yu, J., Zhao, F., Zhou, Y., Shen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877939 · Cited by 31
Regulation of T cell repertoires by commensal microbiota
Kim, K. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1004339 · Cited by 36
“Anti-CTLA-4 treatment weakens the intestinal barrier and permits microbial translocation and systemic circulation of microbe-derived inosine (Mager et al., 2020).”
BackgroundOral administration of the commensal Alistipes onderdonkii prolongs allograft survival
Li, Z., Rasic, M., Kwan, M., Sepulveda, M., Mcintosh, C. M., Shastry, V., Chen, L., Finn, P. W., Perkins, D. L., & Alegre, M. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.011 · Cited by 30
The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer
Strickland, L. N., Faraoni, E. Y., Ruan, W., Yuan, X., Eltzschig, H. K., & Bailey, J. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1163585 · Cited by 33
“In addition, the role of the gut microbiome or intrapancreatic bacteria or fungi may also elevate adenosine or inosine levels elevating the importance of targeting this pathway for cancer treatment (133, 134).”
BackgroundMicrobiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response
Chai, Y., Huang, Z., Shen, X., Lin, T., Zhang, Y., Xu, F., Mao, Q., & Liang, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11051240 · Cited by 29
“Some pieces of evidence gradually confirmed that the microbiota can interact with the host to regulate antitumor immunity to shape cancer development and to impact the response to tumor therapy, particularly ICIs [26–28,183,184].”
BackgroundInfluentialThe Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy
Qi, X., Liu, Y., Hussein, S., Choi, G., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Cells · doi:10.3390/cells11223684 · Cited by 30
Li, M., Wu, X., Jing, W.-Q., Hou, W.-K., Hu, S. C., & Yan, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06017-2 · Cited by 31
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Muscolino, P., Granata, B., Omero, F., Pasquale, C. D., Campana, S., Calabrò, A., D’Anna, F., Drommi, F., Pezzino, G., Cavaliere, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247614 · Cited by 29
“The bacterial metabolite,inosine, mainly derived from Bifidobacterium species, also positively impacted ICI efficacy, by inducing both the activation of CD4+ T and CD8+T cells and robust IFN-g release (33).”
BackgroundWu, H., Deng, M., Xue, D., Guo, R., Zhang, C., Gao, J., & Li, H. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04654-3 · Cited by 30
“…Akkerman-sia muciniphila can increase the levels of CD8+ T cells in tumors by secreting adenosine, subsequently inducing the differentiation and activation of CD4+ T cells and promoting the production of IFN-γ, thus participating in immune regulation and promoting antitumor immune responses [38].”
BackgroundCheng, W., Li, F., & Yang, R. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.05.012 · Cited by 31
Developing functional hydrogels for treatment of oral diseases
Song, C., Liu, R., Fang, Y., Gu, H., & Wang, Y. (2024) · Smart Medicine · doi:10.1002/smmd.20240020 · Cited by 29
Zhang, G., Pan, J., Xu, X., Nie, S., Lu, L., Jing, Y., Yang, F., Ji, G., & Xu, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143323 · Cited by 32
Microbiota-dependent metabolites – New engine for T cell warriors
Tang, Y., Fu, A., Wang, L., & Ge, Q. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2523815 · Cited by 31
“57”
InfluentialClinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
“A notable example is the ino-sine axis, whereby Bifidobacterium pseudolongum -derived inosine ligates the A2A receptor on CD8 + T cells, lowering their activation threshold and boosting IFN-γ production [18].”
Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 36
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
“Inosine was shown to activate antitumour T cells systemically 91 , and oral inosine enhanced ICI efficacy in a phase II trial for advanced solid tumours 181 .”
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Mao, B., Guo, W., Tang, X., Zhang, Q., Yang, B. K., Zhao, J., Cui, S., & Zhang, H. (2022) · Nutrients · doi:10.3390/nu14142830 · Cited by 29
“found that microbiome-derived inosine could levate the effects of ch ckpoint blockade immunotherapy by activating antitumor T cells [10].”
BackgroundInfluentialIgniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 33
Qin, Q., Li, Z., Zhang, M., Dai, Y., Li, S., Wu, H., Zhang, Z., & Chen, P. (2023) · Poultry Science · doi:10.1016/j.psj.2023.102713 · Cited by 31
“Olsenella regulates and enhances the immunotherapy response by producing the metabolite inosine (Mager et al., 2020).”
BackgroundDingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 31
“…CRC mouse model with anti-CTLA-4 or anti-PD-L1 led to smaller and fewer tumors, reduced cancer stem cells, increased immune cell in fi ltration into tumors, increased CD8 + T-cell frequencies in tumor draining lymph nodes and increased splenic CD4 + and CD8 + T-cell activation (Mager et al., 2020).”
MethodHe, J., Li, H., Jia, J., Liu, Y., Zhang, N., Wang, R., Qu, W., Liu, Y., & Jia, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00157-9 · Cited by 34
“Adenosine translocation can activate anti-tumour T cells and enhance ICI efficacy [160].”
BackgroundScoping review protocol on the impact of antimicrobial resistance on cancer management and outcomes
Bratti, V. F., Wilson, B. E., Fazelzad, R., Pabani, A., Zürn, S. J., Johnson, S., Sung, L., & Rodin, D. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068122 · Cited by 28
Maesaka, K., Sakamori, R., Yamada, R., Doi, A., Tahata, Y., Ohkawa, K., Oshita, M., Miyazaki, M., Yakushijin, T., Nozaki, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281459 · Cited by 30
“Three bacterial species that enhanced the efficacy of ICIs (Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species) were isolated in mouse models [39].”
BackgroundHwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 29
Zhang, Y., Zhao, M., He, J., Chen, L., & Wang, W. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.129174 · Cited by 27
Che, Y., Li, L., Kong, M., Geng, Y., Wang, D., Li, B., Deng, L., Chen, G., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1459342 · Cited by 27
“It is demonstrated that Olsenella enhances immunotherapy responses via the production of the metabolite inosine (66).”
BackgroundInosine: novel microbiota-derived immunostimulatory metabolite
Kroemer, G., & Zitvogel, L. (2020) · Cell Research · doi:10.1038/s41422-020-00417-1 · Cited by 28
Golonka, R. M., & Vijay–Kumar, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.004 · Cited by 29
Interleukin-7 protects CD8 + T cells from adenosine-mediated immunosuppression
Koyaş, A., Tüçer, S., Kayhan, M., Savas, A. C., Akdemir, I., & Cekic, C. (2021) · Science Signaling · doi:10.1126/scisignal.abb1269 · Cited by 30
“On the basis of our work here and a study indicating that microbiome-derived inosine increases checkpoint blockade responsiveness through A2AR signaling (24), negative predictors (adora2a and IL-7 signature or microbiome/growth factor signature) of therapy response can also be identified to further stratify the correc…”
BackgroundJing, N., Wang, L., Zhuang, H., Jiang, G., & Liu, Z. (2021) · Cancers · doi:10.3390/cancers13163987 · Cited by 30
“McCoy and coworkers [32] confirmed that Bifidobacterium pseudolongum and Lactobacillus johnsonii could significantly enhance the CD8+ T cell responses in the tumor microenvironment (TME) consistent with the improved efficacy of anti-PD-L1 and anti-CTLA-4 therapy on colorectal cancer.”
BackgroundCancer and immunotherapy: a role for microbiota composition
Pham, F., Moinard‐Butot, F., Coutzac, C., & Chaput, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.051 · Cited by 29
Xiong, Y.-H., Wu, L. M., Shao, L., Wang, Y., Huang, Z., Huang, X., Li, C., Wu, A., Liu, Z., Fan, X., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.811399 · Cited by 34
Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy
Bae, J., Park, K., & Kim, Y. (2022) · Immune Network · doi:10.4110/in.2022.22.e3 · Cited by 32
“Recently, McKoy and colleagues showed that Bifidobacterium pseudolongum is frequently found in tumor tissues of mouse orthotopic colorectal cancer models after immunotherapy with anti-CTLA-4 or anti-PD-L1 Ab (72).”
BackgroundThe Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
Oster, P., Vaillant, L., McMillan, B., & Velin, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899161 · Cited by 32
“These microbiota derived-molecules modulate the mucosal and systemic immune responses (20, 71, 136) and may potentially decrease cancer immunotherapy effectiveness in H pylori infected hosts (19).”
BackgroundMethodMicrobial mechanisms to improve immune checkpoint blockade responsiveness
Griffin, M. E., & Hang, H. C. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100818 · Cited by 31
Guo, W., Cui, S., Tang, X., Zhang, Q., Zhao, J., Mao, B., & Zhang, H. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09986-6 · Cited by 28
“For example, recent reports have exhibited that Lactobacillus modulates the host’s immune system by producing inosine [19].”
ResultThe impact of the microbiome in cancer: Targeting metabolism of cancer cells and host
Huang, J., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029033 · Cited by 28
“Several studies have demonstrated the vital role of gut microbiota in ICIs treatment for melanoma.”
BackgroundInfluentialThe Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond
Eladwy, R. A., Vu, H. T., Shah, R., Li, C. G., Chang, D., & Bhuyan, D. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021716 · Cited by 27
Ding, N., Cheng, Y., Liu, H., Wu, Y., Weng, Y., Cui, H., Chen, C., Zhang, W., & Cui, Y. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02759-22 · Cited by 32
“Robust studies have proven the important roles of the gut microbiota in cancer development (8), progression (9, 10), metastasis (11–13), and even immunotherapy responses (14, 15).”
BackgroundLi, T., Han, L., Ma, S., Lin, W., Ba, X. W., Yan, J., Huang, Y., Tu, S., & Qin, K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1140325 · Cited by 29
“Bifidobacterium pseudolongum enterica can enhance the response to immunotherapy by producing the metabolite inosine (Mager et al., 2020).”
BackgroundGebeyew, K., Yang, C., He, Z., & Tan, Z. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11620-4 · Cited by 32
Topiramate alters the gut microbiome to aid in its anti-seizure effect
Thai, K., Taylor, M. W., Fernandes, T., Akinade, E. A., & Campbell, S. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1242856 · Cited by 31
Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma
Zhang, H., Hong, Y., Wu, T., Ben, E., Li, S., Hu, L., & Xie, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401967 · Cited by 27
Song, H., Tang, X., Liu, M., Wang, G., Yuan, Y., Pang, R., Wang, C., Zhou, J., Yang, Y., Zhang, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110682 · Cited by 28
“44 In our study, single-cell sequencing analysis revealed a strong correlation between the nucleotidemetabolism of breasttumorcellsand the activationof Treg cells,and thisassociationmaybe linkedto theadenosinereceptor, A2AR (Figure2I; Table S3).”
Mei, L., Wang, J., Hao, Y., Zeng, X., Yang, Y., Wu, Z., & Ji, Y. S. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2024.2416481 · Cited by 29
“The purine nucleoside inosine is recognized for its immunomodulatory properties and has been demonstrated to enhance the effectiveness of checkpoint inhibitor immunotherapy, thereby contributing to antitumor immunity (Mager et al. 2020).”
Wang, L., Jiang, W., Yang, M., Danzeng, Q., Liu, S., & Cui, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02275-z · Cited by 29
“Mager et al. found that the inosine from Bifidobacterium pseudolongum activates the adenosine A 2 A receptor specifically on T cells, promoting the activation of TH1 cells as well [71].”
Influence of the microbiome on solid organ transplant survival
Pirozzolo, I., Li, Z., Sepulveda, M., & Alegre, M. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.004 · Cited by 27
The microbiome, gastrointestinal cancer, and immunotherapy
Newsome, R. C., Yang, Y., & Jobin, C. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15742 · Cited by 28
Wu, J., Man, D., Shi, D., Wu, W., Wang, S., Wang, K., Li, Y., Yang, L., Bian, X., Wang, Q., et al. (2022) · Nutrients · doi:10.3390/nu14245311 · Cited by 29
“For instance, inosine is therapeutically useful in enhancing the efficacy of immune checkpoint blockade [32,33].”
BackgroundKnisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 32
“muciniphilia and Bifidobacterium pseudolongum, among other species, has been found to enter systemic circulation and promote Th1 activation, thereby improving the efficacy of ICI [26].”
BackgroundFeng, X., Li, Z., Guo, W., & Hu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1087755 · Cited by 28
Ueki, H., Kitagawa, K., Kato, M., Yanase, S., Okamura, Y., Bando, Y., Hara, T., Terakawa, T., Furukawa, J., Nakano, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37234-6 · Cited by 28
Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?
Dicks, L. M. T., & Vermeulen, W. (2022) · Microorganisms · doi:10.3390/microorganisms10091733 · Cited by 25
Said, S., & Ibrahim, W. (2025) · Cancer Management and Research · doi:10.2147/cmar.s405590 · Cited by 25
Cheng, Y., Huang, X., Li, L., Liu, L., Zhang, C., Xiang, F., Xie, Y., Zou, Y., Geng, Z., & Huang, C. (2023) · Molecules · doi:10.3390/molecules28145498 · Cited by 25
“reported benefits of Colidextribacter on reducing LPS-induced liver damage and inflammation [67], for example.”
BackgroundHan, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 27
Application Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 34
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 33
“On the other hand, the GM can impact local and systemic anti-tumor immune responses by means of metabolites, such as inosine (44) and short-chain fatty acids (82), which may be the link between GM and CI efficacy.”
BackgroundResultInfluentialWu, C.-R., Sun, W., Huang, Y., Dai, S. L., Peng, C., Zheng, Y., Chen, C., & Hao, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.904193 · Cited by 29
“johnsonii was recently shown to significantly enhance the efficacy of immune checkpoint inhibitors in models of cancer and has broad application prospects for the treatment of cancer (microbebased adjuvant therapy) (Mager et al., 2020).”
BackgroundQin, F., Li, J., Mao, T., Feng, S., Li, J., & Lai, M. (2023) · Metabolites · doi:10.3390/metabo13030451 · Cited by 30
“Multiple evidence suggests that numerous gut microbes metabolites may contribute to host metabolism, such as trimethylamine (TMA) [32], inosine [33], indole propionic acid (IPA) [34], phenylacetylglutamine(PAGln) [35], N,N,N-trimethyl-5-aminovaleric acid (TMAVA) [36].”
BackgroundMicrobial metabolites and immunotherapy: Basic rationale and clinical indications
Kovtonyuk, L. V., & McCoy, K. D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101755 · Cited by 27
Self-citationHuang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
“151 By specifying the connection between gut microbiota metabolites and immunotherapy, we may pioneer a new approach to adjuvant cancer treatment.”
BackgroundAdvances in the Relationships Between Cow’s Milk Protein Allergy and Gut Microbiota in Infants
Yang, Y., Li, X., Ying, Y., Shoaie, S., Zhang, C., Ji, B., & Wei, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.716667 · Cited by 27
Gut microbiota and immune alteration in cancer development: implication for immunotherapy
Lau, H. C.-H., Zhang, X., & Yu, J. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100007 · Cited by 25
“13 Gut microbiota and immunotherapy response in HCC The anti- PD-L1 antibody atezolizumab and the vascular endothelial growth factor-neutralising antibody bevacizumab combined therapy has been approved as the first-line therapy for HCC by the FDA, European Medicines Agency and other regulatory…”
Hsu, J., Donahue, R. N., Katragadda, M., Lowry, J., Huang, W., Srinivasan, K., Guntas, G., Tang, J., Servattalab, R., Moisan, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0258 · Cited by 27
“It has been suggested that the responsiveness of syngeneic mouse tumor models to immunotherapy might be affected by either the mouse strain used or environmental factors, such as mouse housing conditions, that might modulate the murine microbiome ( 36 , 37 ).”
BackgroundThe Role of Gut Microbiota in Modulating Cancer Therapy Efficacy
Madkour, M. A., Altaf, R. A., Sayed, Z. S., Yasen, N. S., Elbary, H. A., Elsayed, R. A., Mohamed, E. N., Toema, M., Wadan, A.-H. S., Nafady, M. H., et al. (2024) · Advanced Gut & Microbiome Research · doi:10.1155/2024/9919868 · Cited by 25
Potential of natural products and gut microbiome in tumor immunotherapy
Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 27
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
“Moreover, it was observed that mice monocolonized with Bi fi dobacterium pseudolongum had a bacterial metabolite named inosine present in their sera, which helps with antitumor T cell activation (233).”
The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Čierniková, S., Novisedláková, M., Cholujová, D., Števurková, V., & Mego, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120565 · Cited by 24
“Recently, an association between the microbiome-derived inosine and enhanced efficacy of checkpoint blockade immunotherapy in mice with colorectal, bladder, and melanoma tumors has been discovered [55].”
BackgroundGreisen, S. R., Aspari, M., & Deleuran, B. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883733 · Cited by 27
“Considering the evolving evidence of the major significance of the microbiota in the development of autoimmune diseases, including both rheumatic and gastrointestinal diseases, the role of CTLA-4, in combination with PD-1 is further highlighted by both their abilities to influence IgA synthesis and the microbiome (78,…”
BackgroundGuo, W., Cui, S., Tang, X., Yan, Y., Xiong, F., Zhang, Q., Zhao, J., Mao, B., & Zhang, H. (2023) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.12665 · Cited by 27
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
Park, J. S., Gazzaniga, F. S., Kasper, D. L., & Sharpe, A. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01075-0 · Cited by 25
“In other cases, the impact of colonization with speci fi c bacteria is only observed in the context of disease settings 10,11 .”
Wang, S., Xu, B., Zhang, Y., Chen, G., Zhao, P., Gao, Q., & Yuan, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0376 · Cited by 32
“Inosine, a bacterial metabolite produced by Bifidobacterium pseudolongum and Akkermansia muciniphila , promotes Th1 cell activation and modulates the enhanced immunothera-peutic response through the T cell-specific A 2A R signaling pathway 119 .”
Background
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.